HLB테라퓨틱스

115450KOSDAQ기타 전문 도매업

44.2 / 100

Reference Date: 2026-04-13

Financial Score9.5 / 40

News Sentiment16.7 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Rose 11.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Therapeutics operates three core business divisions: biopharma, cold chain, and electronics. Through numerous mergers and acquisitions since 2013, the company has diversified its business, and after divesting its electronics division in 2024, it continues to transition toward a biopharma-focused structure. Its main revenue streams come from vaccine pharmaceuticals and distribution fees.

Number of Employees

50people

Average Salary

48.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.634.0Point

PBR

1.69Industry Average 0.630.0Point

2.7x industry avg (risky)

ROE

-5.44Industry Average 2.090.0Point

Well below industry avg

Debt Ratio

16.44Industry Average 7.870.0Point

2.1x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲14.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲33.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -6.9% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 2Neutral 0Negative 0Average Sentiment Score 75

Positive
진양곤 HLB그룹 의장, 올해 16차례 계열사 주식 매수
진양곤 HLB그룹 의장이 올해 들어 HLB테라퓨틱스를 포함한 계열사 주식을 16차례 매수하며 책임경영 의지와 미래 성장성에 대한 자신감을 표명했습니다.
Positive
진양곤 HLB그룹 의장, 계열사 지분 확대 지속…"미래 성장성 자신감...
진양곤 HLB그룹 의장이 HLB테라퓨틱스 등 계열사 지분 확대를 지속하며 기업의 미래 가치와 성장 동력에 대한 자신감을 드러냈습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 3,320Won52-week high 9,10852-week low 2,424

1-month return5.0Point

1m +11.78% (rising)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

11 totalPositive 0Neutral 11Negative 0

Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-04-01
Neutral본점소재지변경2026-03-27
Neutral정기주주총회결과2026-03-27
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
Neutral기업설명회(IR)개최2026-03-25